The Innate Immune Response to Herpes Simplex Virus 1 Infection Is Dampened in the Newborn Brain and Can Be Modulated

Daniel Giraldo1, Douglas R Wilcox2,3,4, Richard Longnecker5

  • 1Department of Microbiology and Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

Mbio
|May 28, 2020
PubMed

Insights

Newborns are highly susceptible to herpes simplex virus 1 (HSV-1) infection due to dampened interferon (IFN) signaling in the brain. Interferon beta (IFN-β) treatment improved survival in newborns, suggesting a potential therapeutic strategy.

Area of Science:

  • Immunology
  • Virology
  • Neuroscience

Background:

  • Newborns exhibit increased susceptibility to severe herpes simplex virus 1 (HSV-1) infections like encephalitis compared to adults.
  • Age-dependent immune response differences, particularly in the brain, are not well understood.
  • HSV-1 infection in newborns can lead to fatal outcomes or severe neurological sequelae despite treatment.

Purpose of the Study:

  • To investigate age-dependent differences in the innate immune response to HSV-1 infection.
  • To determine the role of interferon (IFN) signaling in the newborn brain's susceptibility.
  • To explore the therapeutic potential of exogenous IFN-β in newborn HSV-1 infection.

Main Methods:

  • Utilized a murine model of HSV-1 infection to compare newborn and adult mice.
  • Assessed basal-level expression of innate immune signaling pathways.
  • Administered exogenous interferon beta (IFN-β) to newborn mice with disseminated HSV-1 infection.

Main Results:

  • Newborn mice showed higher susceptibility to HSV-1 infection than resistant adult mice.
  • Dampened type I interferon (IFN) signaling was observed in the newborn brain.
  • IFN-β treatment significantly increased newborn survival, delayed neuroinvasion, and stabilized the blood-brain barrier (BBB).

Conclusions:

  • Significant age-dependent differences exist in the innate immune response to HSV-1.
  • The blood-brain barrier (BBB) and brain parenchyma contribute to newborn susceptibility.
  • Exogenous IFN-β shows promise as a therapeutic strategy for neonatal HSV-1 infections.